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ABSTRACT
DNA topoisomerase IIa (topo IIa) is an essential
nuclear enzyme and its unique decatenation activity
has been implicated in many aspects of chromo-
some dynamics such as chromosome replication
and segregation during mitosis. Here we show that
chromatin-associated protein HMGB1 (a member
of the large family of HMG-box proteins with
possible functions in DNA replication, transcription,
recombination and DNA repair) promotes topo
IIa-mediated catenation of circular DNA, relaxation
of negatively supercoiled DNA and decatenation of
kinetoplast DNA. HMGB1 interacts with topo IIa and
this interaction, like the stimulation of the catalytic
activity of the enzyme, requires both HMG-box
domains of HMGB1. A mutant of HMGB1, which
cannot change DNA topology stimulates DNA
decatenation by topo IIa indistinguishably from the
wild-type protein. Although HMGB1 stimulates ATP
hydrolysis by topo IIa, the DNA cleavage is much
more enhanced. The observed abilities of HMGB1 to
interact with topo IIa and promote topo IIa binding
to DNA suggest a mechanism by which HMGB1
stimulates the catalytic activity of the enzyme via
enhancement of DNA cleavage.
INTRODUCTION
DNA topoisomerase II (topo II) is an essential and
ubiquitous enzyme for proliferation of eukaryotic cells (1).
It can alter the topological state of DNA and untangle
DNA knots and catenanes (interlocked rings) via
ATP-dependent passing of an intact double helix through
a transient double-stranded break generated in a separate
DNA segment, followed by religation and enzyme turn-
over (2). In mammalian cells, topo II exists in two
isoforms, a (170kDa) and b (180kDa), both having
similar primary structure and almost identical catalytic
properties, but diﬀering in their production during the
cell cycle (1,3).
Topo II is the primary target of a number of active
agents currently used in the treatment of human
cancers, such as epipodophyllotoxins (etoposide and
teniposide), anthracyclines (doxorubicin and daunorubi-
cin) and mitoxantrone (3). These drugs (also termed
topo II poisons) can stabilize the covalent enzyme-
associated complexes and shift the DNA cleavage/
religation equilibrium of the enzyme reaction toward
the cleavage state, converting biological intermediates
of topo II activity into lethal ones ultimately leading
to triggering of programmed cell death pathways
(1,3,4).
HMGB1 is an abundant, ubiquitous and evolutionarily
highly conserved non-histone chromatin-associated
protein in mammals, which functions in a number of
fundamental cellular processes such as transcription,
replication, DNA repair and recombination (5–8).
HMGB1 is associated with chromosomes in mitosis
and due to its extreme mobility in the cell, the protein is
continuously exchanged between nucleus and cytoplasm
(5 and references therein). HMGB1 also exhibits an
important extracellular function in mediation of inﬂam-
mation mechanisms, tumor growth and metastasis (5,6).
HMGB1 binds relatively weakly to B-form DNA, but
displays a high aﬃnity for distorted DNA conformations
[e.g. four-way DNA junction, DNA minicircles, hemi-
catenated DNA loops and cisplatin-modiﬁed DNA;
(7–12)]. Binding of HMGB1 to DNA causes local
distortions by bending/looping or changes of DNA
topology (7,13,14). HMGB1 also interacts weakly with
a number of proteins, including transcription factors,
site-speciﬁc recombination and DNA repair proteins (5).
The importance of HMGB1 for life is supported by
the phenotype of the HMGB1 knockout mice, which die
24h after birth due to hypoglycemia and exhibit a defect
in the transcriptional function of the glucocorticoid
receptor (15).
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between HMGB1 and human topo IIa in vitro. We show
that HMGB1 promotes topo IIa-mediated catenation of
circular DNA, enhances relaxation of negatively super-
coiled DNA and decatenation of kinetoplast DNA.
Stimulation of the catalytic activity of topo IIa by
HMGB1 is mainly due to enhanced DNA binding and
cleavage by the enzyme. Possible functioning of HMGB1
as a modulator of the cellular activity of topo IIa is
discussed.
MATERIALS AND METHODS
Enzymes andantibodies
Experiments were carried out either with human topo-
isomerase IIa (topo IIa) purchased from Topogen, or with
recombinant human topo IIa isolated from yeast strain
JEL1top1 (the strain was kindly provided by John L.
Nitiss, Department of Molecular Pharmacology, St. Jude
Children’s Research Hospital, Memphis, USA) harboring
plasmid YEpWOBalphaHT (kindly provided by Anni H.
Andersen, Department of Molecular Biology, University
of Aarhus, Aarhus, Denmark) as detailed in references
(16–18). Escherichia coli topoisomerase IV (10U/ml) and
wheat germ topoisomerase I (2–10U/ml) were purchased
from Topogen and Promega, respectively. Kinetoplast
DNA (kDNA) was isolated from Crithidia fasciculata
(the cells were kindly provided by Paul T. Englund,
Haskins Laboratories and Biology Department, Pace
University, New York, USA) as detailed in (19). kDNA
was also kindly provided by Julius Lukesˇ (Institute of
Parasitology, C ˇ eske ´ Bude ˇ jovice, Czech Republic).
Antibodies against the following proteins were used:
anti-HMGB1 (aﬃnity puriﬁed rabbit polyclonal, BD
Pharmingen), and anti-topo IIa (rabbit polyclonal,
Topogen).
Plasmids
DNA plasmids were isolated by alkaline lysis method,
followed by puriﬁcation by two rounds of cesium chloride
gradient or by the Qiagen plasmid kits. All puriﬁed
plasmids exhibited ratios A260/A280 higher than 1.85.
In some cases (catenation assays), supercoiled plasmids
pTZ19R or pBR322 were relaxed by wheat germ
topoisomerase I, followed by deproteinization of the
relaxed plasmid as detailed earlier (20).
Cloning ofHMGB1 and site-directed mutagenesis
HMGB1 (residues 1–215), HMGB1 domain A (residues
1–88), HMGB1 domain B (residues 85–180) and HMGB1
di-domain A+B (residues 1–180) were derived from
rat HMGB1 cDNA (the amino acid sequence of the rat
HMGB1 protein is identical to that of the human
HMGB1 protein). Alanine mutagenesis of intercalating
residues Phe38 (domain A), Phe103 and I122 (domain B)
of the individual HMGB1 domains or the full-length
HMGB1 was carried out using PCR-based protocol
generating ‘chimeric proteins’ (S ˇ tros, unpublished
data). The introduced mutations were veriﬁed by
dideoxi-sequencing of both strands. The DNA sequences
coding for the HMGB1 and truncated forms were inserted
into BamHI and SalI sites of the vector pQE-80L (Qiagen)
which allows tightly regulated N-terminal 6xHis-tagged
protein expression in E. coli. The N-terminally GST
(Glutatione S-Transferase) tagged HMGB1 protein
and its truncated forms were also synthetized from
the pGEM-4T1 vector (GE Healthcare). Puriﬁcation of
HMGB1 proteins by FPLC-chromatography, and SDS–
18% polyacrylamide gel electrophoresis was performed
as described earlier (11,21,22).
DNA supercoiling assay
DNA supercoiling assay was carried out as previously
described (20) with the following modiﬁcations.
Negatively supercoiled plasmid pBR322 DNA (0.5mgo r
 9nM) was relaxed in the relaxation buﬀer (40mM NaCl,
50mM Tris-HCl pH 7.5, 1mM EDTA, 20% glycerol,
1mM DTT) by wheat germ topoisomerase I (2U,
Promega) at 378C for 90min. Then a new portion
of the enzyme was added and the relaxed DNA was
subsequently mixed either with wild-type HMGB1
or mutated HMGB1 (0–6mM) in a ﬁnal volume of 20ml.
The reactions were allowed to proceed for 1h at 378C
after which 5ml of the termination mix (5  TBE, 5%
SDS, 15% sucrose, 0.1% bromphenol blue, 0.1% xylene
cyanol, 0.2mg/ml proteinase K in 20mM Tris-HCl pH
8.0,1mM CaCl2) was added and the samples were
incubated at 458C for 30min, followed by phenol/chloro-
form extraction (11). The DNA topoisomers were
then resolved on a 1% agarose gel in 0.5  TBE buﬀer
at  3V/cm for 17h, and the DNA samples were visualized
by UV-illumination of the ethidium bromide-stained gel
(0.5mg/ml).
Enhancement of intermolecular DNA ligation by HMGB1
Supercoiled plasmid pTZ19R ( 15nM) was linearized by
HindIII digestion, the deproteinized linear DNA was
mixed with HMGB1 (2 or 6mM), and pre-incubated on ice
for 20min. The DNA was then ligated with 0.2U of T4
DNA ligase in a ﬁnal volume of 20mla t3 0 8C for 30min in
the presence or absence of 5% (w/v) polyethylene glycol
(PEG 8000, Sigma). Deproteinized DNA samples were
resolved on 1% agarose gels, followed by staining with
ethidium bromide (0.5mg/ml).
Human topoisomerase IIa catalyticactivity assays
The following assays were used to assess topo IIa activity:
catenation, decatenation, relaxation, cleavage and religa-
tion. Most experiments were carried out both with human
topo IIa purchased from Topogen and with recombinant
human topo IIa isolated from yeast (see ‘Materials and
Methods section’). ‘Catenation assay’ was carried out with
either negatively supercoiled or relaxed closed-circular
plasmids. The plasmid pTZ19R ( 15nM) was pre-
incubated on ice in a total volume of 20ml of topo IIa
assay buﬀer (50mM Tris-HC1 pH 8, 85mM KCl, 10mM
MgCl2, 1mM ATP, 0.5mM dithiothreitol, 30mg/ml BSA)
containing 0–10% PEG (w/v) with diﬀerent amounts of
HMGB1 (as indicated in the ﬁgure legends) for 20min,
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mixture was ﬁnally incubated at 378C for 40–60min.
‘Decatenation assay’ was performed in the topo IIa
assay buﬀer by incubation of 0.2mg of kinetoplast DNA
(kDNA) with topo IIa (as indicated in the ﬁgure legends).
No PEG was present in the decatenation assay buﬀer.
‘Relaxation assay’ was carried out in the topo IIa assay
buﬀer by treatment of negatively supercoiled plasmid
pBR322 ( 8nM) with either a ﬁxed amount of topo IIa
and increasing amounts of HMGB1 or with increasing
amounts of topo IIa and a ﬁxed amount of HMGB1 as
indicated in the ﬁgure legends. No PEG was present in the
relaxation assay buﬀer. All other reaction conditions of
the relaxation assay were identical to the catenation assay.
The above topo IIa activity assays were terminated by
rapid addition of 460ml of 1M NaCl/1% SDS/10mM
EDTA and 2ml of 2.5% linear polyacrylamide as
carrier, followed by vortexing with an equal volume of
chloroform–isoamylalcohol (24:1, v/v). The mixtures were
then centrifuged at room temperature at 10000g for
10min, and the clariﬁed upper layers were precipitated
with 1ml of absolute ethanol at  708C for 20min. The
DNA precipitates were washed with 70% ethanol, air-
dried and dissolved in 0.1  TE buﬀer. ‘DNA cleavage
assay’ was carried out by incubation of plasmid pBR322
( 4nM) with topo IIa in DNA cleavage buﬀer (10mM
Tris-HCl pH 8, 50mM KCl, 50mM NaCl, 5mM MgCl2,
2.5% glycerol, 0.1mM EDTA, containing either 1mM
ATP or 1mM non-hydrolyzable analog ANP-PNP,
Sigma) in a total volume of 20mla t3 7 8C for 20min.
Some reactions also contained HMGB1 (1–3mM) and/or
etoposide (10–100mM, Sigma) as indicated in the ﬁgure
legends. The cleavage reactions were terminated by
trapping the DNA cleavage complexes by addition of
2ml of 10% SDS, followed by addition of 1.5ml of 0.25M
EDTA and 2ml of proteinase K (0.8mg/mli n5 0 m M
Tris-HCl pH 8, and 1mM CaCl2) and incubation at 458C
for 60min. ‘Religation assay’ was carried out in DNA
cleavage buﬀer containing 30ng BSA (bovine serum
albumin)/ml in a DNA mixture with negatively supercoiled
plasmid pBR322 (4nM), 50mM etoposide, and topo IIa
(8nM). In some cases, HMGB1 (1–3mM) was pre-
incubated with DNA for 20min on ice before addition
of the enzyme. The reactions were started by incubation at
378C for 15min, followed by shifting the incubation
temperature to 658Co r7 5 8C (to promote only the topo
IIa-mediated religation and not the cleavage). Aliquots
(20ml) were then withdrawn at diﬀerent times (typically
0–40min), immediately mixed with 2.2ml of 10% SDS,
and ﬁnally digested with proteinase K (see ‘DNA cleavage
assay’). The deproteinized DNA samples were ﬁnally
resolved on 1% agarose gels containing 0.5  TBE. DNA
was visualized by ethidium bromide staining which
was either present in the gels prior to electrophoresis
(DNA decatenation, cleavage and religation assays), or
gels were stained after electrophoresis (DNA relaxation
and catenation assays). DNA was quantiﬁed either
using the ImageQuant TL software (GE Healthcare)
or Multi Gauge software using imaging system
LAS-3000 (Fuji).
Decatenation of kDNA by E. coli topoisomerase IV
Decatenation assay was carried out with 0.2mg of kDNA
in 40mM HEPES-KOH (pH 7.6), 100mM potassium
glutamate, 10mM magnesium acetate, 2mM ATP, 10mM
DTT and 50mg BSA/ml with E. coli topoisomerase IV
(typically 0.1–1U) in the presence or absence of HMGB1
(1 or 4mM) in a ﬁnal volume 20mla t3 7 8C for 30min,
according to the manufacturer’s instructions (Topogen).
Analysis of decatenated products was performed as
detailed for decatenation by human topo IIa.
Electrophoretic mobility shift assay
The 36-mer oligonucleotides for EMSA containing a
high-aﬃnity topo IIa-binding site (47,48) were (50 to 30):
oligo_1, ATGAAATCTAACAATGCGCTCATCGTCA
TCCTCGGC; oligo_2, GCCGAGGATGACGATGAG
CGCATTGTTAGATTTCAT.
The oligo_1 was
32P-labeled at its 50-terminus by T4 DNA
kinase and [g-
32P]ATP (speciﬁc activity 3000Ci/mmol, GE
Healthcare) and annealed with its corresponding comple-
mentary strand (oligo_2) to form a DNA duplex. Reaction
mixtures for EMSA contained isolated topo IIa (75nM)
and increasing amounts of HMGB1 proteins (0.4–1.6mM),
 35ng of
32P-labeled DNA duplex in EMSA buﬀer (20mM
HEPES, pH 7.6, 4% Ficoll, 0.02% Nonidet P-40,
1.5mM spermidine, 0.1mM EDTA, 0.125 M KCl and
0.5mM DTT) in a total volume of 20ml. In some EMSA
assays, 0.2mg of homopolymer poly (dI-dC) was used as a
non-speciﬁc competitor DNA to reduce non-sequence
speciﬁc binding of HMGB1. However, we have noticed
that the presence of the competitor DNA signiﬁcantly
reduced the binding of topo IIa to the linear 36-bp
DNA duplex as previously reported (23). The proteins
were pre-incubated with DNA on ice for 20min (order of
mixing had no eﬀect on the outcome of the EMSA assays)
and ﬁnally resolved on 5% polyacrylamide gels in 0.5  TBE
buﬀer at 250V at 48C until the bromphenol blue reached
the bottom of the gel. The gels were dried and the
labeled DNA was imaged by Storm PhosphorImager
(Molecular Probes).
ATPhydrolysis by topoisomerase IIa
ATP hydrolysis was studied in reactions containing 1mM
cold ATP plus 20 10
6c.p.m. of [g-
32P]ATP (speciﬁc
activity 3000Ci/mmol, GE Healthcare) and negatively
supercoiled plasmid pBR322 (50nM). Some reactions also
contained HMGB1 (0.2–3mM). ATP hydrolysis was
initiated by addition of topo IIa (5nM). Termination of
ATP hydrolysis was accomplished by spotting the
mixtures on TLC cellulose plates (20 20cm; Baker-ﬂex,
Phillipsburg) at diﬀerent times as previously described
(24). Products of ATP hydrolysis were separated by thin
layer chromatography and the free phosphate was
quantiﬁed by PhosphorImager.
Electronmicroscopy
Following incubation of the relaxed circular plasmid
DNA with topo IIa and HMGB1, the DNA was
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extraction. RecA coating of DNA for EM was carried out
by the protocols detailed in (25). Brieﬂy, for single-strand
DNA coating with RecA ( 9.1kb plasmid pAK-9.1),
DNA was denatured at 638C in the presence of glyoxal
and puriﬁed on a Sephacryl S-500 minicolumn
(0.4 4cm) (GE Healthcare). Denatured DNA was then
mixed with RecA protein at a molar ratio of 70:1 ( 2.8-kb
plasmid pTZ19R) or 30:1 ( 9.1-kb plasmid pAK-9.1),
cross-linked with 0.2% (v/v) glutaraldehyde, and puriﬁed
on a Sephacryl S-500 minicolumn. Coating of double-
stranded DNA ( 2.8kb plasmid): following DNA coating
with RecA, 0.5mM ATP-gS was added to stabilize the
complexes. DNA cross-linking with glutaraldehyde and
puriﬁcation of the RecA-coated dsDNA was carried out
as for single-stranded DNA. RecA-coated DNA samples
(15ml) were adsorbed to a freshly glow-discharged (26)
carbon-coated parlodion ﬁlm on EM grids. Specimens
were washed with 100mM ammonium acetate, stained
on drops of 5% (w/v) uranyl acetate and washed on the
surface of 10mM ammonium acetate (25). The grids were
both rotary and unidirectionally shadowed with platinum/
palladium at an angle of  78 and observed with a JEOL
JEM 1200EX electron microscope operating at 60kV.
The photographs were taken at 50000 magniﬁcation.
GST pull-down assay
GST alone or GST fused with full-length HMGB1 or its
HMG-box domains at their N-termini were isolated as
described (21,22). The purifed proteins (typically 1–2mg)
were bound to glutathione Sepharose 4B beads (40mlo f
1:1 v/v slurry), and incubated with puriﬁed human topo
IIa (0.5mg) in buﬀer PD [20mM Tris-HCl pH 7.6, 0.2M
NaCl, 10mM DTT, 0.2% Triton X-100, 0.2% Tween-20,
20% glycerol (v/v), protease inhibitors: 1mg/ul aprotinin,
10mg/ul leupeptin, 1mg/ul pepstatin A, 100mg/ul trypsin
inhibitor, 0.1mM TLCK and 20mM benzamidine] in
the presence or absence of 10U of DNAse I for 15min at
258C, followed by rocking the samples for 2h at 48C.
Subsequently, the beads were washed ﬁve times in 1ml of
1  PD buﬀer. The proteins associated with Sepharose
beads were ﬁnally eluted from the beads by addition of
20mlo f1 0   SDS loading buﬀer and boiling the samples
for 3–4min. The beads-associated proteins were resolved
on an SDS–7.5% polyacrylamide gel, transferred onto the
PVDF membrane by western blotting and detected using
polyclonal human topo IIa antibody (1:1000 dilution,
Topogen), followed by incubation of the membranes with
horseradish peroxidase-conjugated anti-rabbit antibodies
(IgG-HRP) (1:2000 dilution, GE Healthcare) and ECL
detection (GE Healthcare).
RESULTS
HMGB1 stimulates interlocking of DNA by human
topoisomerase IIaas revealed by gelelectrophoresis
We have previously shown that chromatin architectural
protein HMGB1 could stimulate T4 DNA ligase-mediated
end-to-end joining of linear DNA molecules by promoting
intramolecular association of DNA molecules via their
ends (21,27). Ligation of diluted solutions of linearized
plasmid DNA in the presence of HMGB1 resulted in
preferential intramolecular ligation into closed-circular
DNA (Figure 1A, lanes 2–4). However, as both DNA
and HMGB1 are present in eukaryotic nuclei in relatively
high concentrations, the eﬀect of the protein on DNA
end-joining was re-investigated in the presence of a
macromolecular crowding (volume excluding) agent,
polyethyleneglycol (PEG), to mimic crowding in vitro.
In the absence of HMGB1, PEG alone had only little
eﬀect on DNA ligation using limiting amounts of the
enzyme (Figure 1A, compare lanes 2 and 5). However,
the simultaneous presence of HMGB1 and PEG sup-
pressed intramolecular ligation and markedly promoted
intermolecular DNA end-joining. Under these conditions,
all monomeric DNA molecules were converted into linear
DNA multimers, the majority of which migrating on
agarose gels with the mobility of trimers or higher
multimers (designated as L3 in Figure 1A), and into a
minor fraction of high molecular mass linear multimers
(which were susceptible, like L3, to ExoIII digestion, data
not shown) not entering the gel (Figure 1A, compare lanes
5 and 7).
The ability of HMGB1 to promote intermolecular
association of DNA prompted us to determine whether
HMGB1 could also promote interlocking (catenation)
of covalently closed DNA by human topoisomerase IIa
(topo IIa). As shown in Figure 1B (lanes 2 and 5),
incubation of supercoiled DNA and HMGB1 with limit-
ing amounts of topo IIa resulted in no formation of DNA
multimers unless 5% PEG was included in the reaction
buﬀer (Figure 1B, lane 6). Most of the complex DNA
multimers did not enter the agarose gel and remained at its
origin. The apparent size of the complex DNA multimers
was visibly decreased at 10% PEG, and a signiﬁcant
fraction of the DNA multimers was no longer trapped in
the wells and migrated rather as discrete bands of lower
mobility (Figure 1B, lane 7).
Stimulation of topo IIa-mediated formation of DNA
multimers by HMGB1 was independent of the topological
state of the initial DNA (Figure 1C). Interestingly,
HMGB1 and topo IIa could induce small changes in
the linking number of relaxed closed-circular DNA at
the highest molar ratio HMGB1-to-DNA studied as
evidenced by the formation of faster migrated DNA
topoisomers (Figure 1C, lane 5). The latter ﬁnding is
reminiscent of the eﬀect of HMGB1 on DNA supercoiling
of closed-circular plasmid DNA by topoisomerase I
(13,14).
In order to characterize the DNA multimers formed by
plasmid DNA, HMGB1 and topo IIa in the presence of
PEG, the deproteinized DNA multimers were treated with
restriction nuclease HindIII or topo IIa. Digestion of the
DNA multimers by HindIII resulted in a single band
corresponding to the linearized plasmid DNA (Figure 1C,
lane 10). The DNA multimers could be resolved into
relaxed circular DNA and a minor fraction of circular
plasmid dimers upon treatment with topo IIa (Figure 1D).
The above results suggested that the DNA multimers
formed by plasmid DNA, HMGB1 and topo IIa in
the presence of PEG represented catenated DNA,
5004 Nucleic Acids Research, 2007, Vol. 35, No. 15i.e. double-stranded DNA molecules interlocked by a
double-stranded DNA pass, rather than hemicatenated
DNA molecules.
Electron microscopy revealsthat DNA catenanesare
formed byHMGB1 andtopoisomerase IIa
In order to further verify that HMGB1 promotes
formation of fully inter-locked DNA molecules by
topo IIa, and to assess the complexity of these multimers,
the DNA complexes were visualized by electron micros-
copy (EM). Prior to EM, the DNA multimers
(originating either from a 2.8-kb or a 9.1-kb plasmid for
double-stranded or single-stranded DNA coating, respec-
tively) were deproteinized, followed by coating with RecA
protein for better imaging of the DNA at cross-over
points. Examination of the samples by EM revealed that
the DNA multimers formed by HMGB1 and topo IIa
contained many linked DNA molecules (>60% of all
visualized DNA samples), and that the majority of these
catenated molecules formed heterogeneous population of
DNA molecules inter-linked with one or several DNA
molecules (Figure 2; no DNA multimers were observed
when DNA was incubated with HMGB1 in the absence of
topo IIa, data not shown). The complex nature of these
DNA multimers revealed by EM (Figure 2) corresponded
to their migration in the course of agarose gel electro-
phoresis: they either remained at the origin of the gel or
migrated with very low mobility (Figure 1), suggesting
their high-molecular mass.
HMGB1 stimulates decatenation ofkinetoplast DNA and
relaxation ofsupercoiled DNA by topoisomerase IIa
To ﬁnd out whether other catalytic activity of topo IIa
than DNA catenation are stimulated by HMGB1, the
eﬀect of HMGB1 on topo IIa-mediated decatenation
of kinetoplast (kDNA) or relaxation of negatively super-
coiled DNA was studied.
To study the eﬀect of HMGB1 on DNA decatenation,
increasing amounts of the topo IIa were added to
kinetoplast DNA (kDNA) in the presence or absence of
HMGB1. As shown in Figure 3A, the amount of
decatenated DNA products increased proportionally
with the amount of added topo IIa, and the decatenation
activity of the enzyme was up to  10-fold higher
Figure 1. HMGB1 promotes intermolecular association of DNA. (A) Macromolecular crowding favors intermolecular ligase-mediated DNA end-
joining by HMGB1. Linearized plasmid pTZ19R ( 15nM) was pre-incubated with 0.5mM (lanes 3 and 6) or 1.5mM (lanes 4 and 7) HMGB1, and
then treated with 0.2U of T4 DNA ligase in the presence (lanes 6 and 7) or absence (lanes 3 and 4) of 5% polyethyleneglycol (PEG). L2, dimers; L3
trimers or higher multimers. Linear, linearized plasmid pBR322; circular, closed-circular plasmid pBR322. (B) HMGB1 promotes topo IIa-catalyzed
interlocking of DNA into multimers (catenanes) in the presence of PEG. Supercoiled plasmid pTZ19R ( 15nM, lane 1) was pre-incubated with
HMGB1 (4.5mM) in the absence or presence of PEG (as indicated), and treated with topo IIa ( 7nM). (C) Both relaxed and supercoiled plasmid
DNAs form multimers with HMGB1 and topo IIa. Relaxed or supercoiled plasmids pTZ19R ( 15nM) were pre-incubated with 0.5mM (lanes 3
and 7), 1.5mM (lanes 4 and 8) and 4.5mM HMGB1 (lanes 5 and 9) in the presence of 5% PEG, followed by treatment with topo IIa ( 7nM).
(D) DNA multimers formed by topo IIa and HMGB1 are catenanes. Reactions from (C) (lane 4) were deproteinized and treated with increasing
amounts of topo IIa (10 and 20nM, left to right) for 30min at 378C. Deproteinized samples in (A–D) were separated on 1% agarose gels, and the
resolved DNA samples were visualized by ethidium bromide staining as detailed in Materials and Methods section. The gels are presented as
negatives. FI, supercoiled plasmid DNA; FII, relaxed closed-circular plasmid DNA; FIII, linearized plasmid DNA (HindIII).
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of HMGB1 as revealed by the densitometry of the band
intensities of the decatenated kDNA minicircles. No
decatenation of kDNA was observed by incubation with
HMGB1 alone in the absence of topo IIa (Figure 3A).
HMGB1 protein consists of two HMG-boxes, domains
A and B, and a highly acidic C-terminus (Figure 3B).
To ﬁnd out which part of HMGB1 is responsible for
stimulation of decatenation of kDNA by topo IIa,
decatenation experiments were carried out with HMGB1
and its truncated forms. As shown in Figure 3C, both
HMGB1 and HMGB1-C could enhance decatenation of
kDNA to a similar extent, suggesting that the HMG-
boxes of HMGB1, and ‘not’ the acidic C-tail, were
responsible for the enhancement of the decatenation
activity of topo IIa. Although both isolated HMGB1
domains, A and B, could decatenate kDNA, the observed
stimulatory eﬀect was signiﬁcantly lower (up to  10-fold)
than that observed with the full-length HMGB1 or the
A+B di-domain (HMGB1-C), Figure 3C.
The fact that complex DNA multimers were formed
under conditions when the relaxation activity of the
enzyme was severely compromised by higher concentra-
tions of PEG, suggested that HMGB1 could also stimulate
the relaxation activity of the enzyme (Figure 1B, compare
lanes 6 and 7). As shown in Figure 3D, when increasing
amounts of topo IIa were incubated with negatively
supercoiled plasmid DNA, DNA was relaxed more
eﬃciently when HMGB1 was present in the reactions.
The above experiments provided evidence that HMGB1
could stimulate both DNA catenation/decatenation
and relaxation of supercoiled DNA by topo IIa. While
PEG was necessary to observe DNA catenation by low
amounts of topo IIa in the presence of HMGB1
(Figure 1), it was clearly dispensable for HMGB1-
mediated stimulation of kDNA decatenation and relaxa-
tion of supercoiled DNA (Figure 3), suggesting that PEG
itself could not stimulate topo IIa activity.
The possibility that HMGB1 might act as a chaperone
for topo IIa protecting it from inactivation during the
course of catalytic assays was excluded based on results
from control experiments in which the enzyme was
incubated in reaction buﬀer in the presence or absence
of HMGB1 prior to addition of DNA (data not shown).
HMGB1-mediated stimulation ofDNA decatenationby
topoisomerase IIaisnot due tothe effectof
HMGB1 on DNA topology
HMGB1 has been known to aﬀect DNA topology by
unwinding or by inducing negative supercoiling
(13,14,20,28). Recently we demonstrated that alanine
mutagenesis of intercalating residues of HMGB1
domains, A (Phe 38) and B (Phe 103 and Ile122)
(Figure 4A and B), abrogated high-aﬃnity binding of
HMGB1 to bent DNA (minicircles) without aﬀecting
signiﬁcantly its aﬃnity to linear DNA (12). Here we show
that the HMGB1 mutant also lost the ability to supercoil
DNA in a topo I-mediated supercoiling assay (Figure 4C).
To ﬁnd out whether the mutated HMGB1 could still
promote the catalytic activity of topo IIa, decatenation of
kDNA was carried out. As shown in Figure 4D, mutated
HMGB1 could promote decatenation of kDNA by topo
IIa indistinguishably from the wild-type protein, suggest-
ing that the observed enhancement of catalytic activity of
topo IIa by HMGB1 was not aﬀected by the HMGB1-
mediated changes in DNA topology.
The speciﬁcity of HMGB1 on the catalytic activity of
human topo IIa was further investigated using E. coli
type-II topoisomerase IV (29). As shown in Figure 4E,
addition of increasing amounts of HMGB1 to the
decatenation reactions did not enhance the activity of
the prokaryotic enzyme. Thus, while the above data ruled
out the eﬀect of HMGB1-mediated changes in DNA
topology on the stimulation of topo IIa activity (and also
E. coli type-II topoisomerase IV), they may suggest an
involvement of protein–protein interactions in the stimu-
latory eﬀect of HMGB1 protein on the catalytic activity
of human topo IIa.
Figure 2. The complex multimers formed by topoisomerase IIa and
HMGB1 consist of fully catenated DNA molecules. Multimers were
formed with plasmid DNA of 9.1kb (panels A–D) or 2.8kb (panels
E–F), HMGB1 and human topoisomerase IIa. The samples were
deproteinized and coated with RecA protein as single-stranded (panels
A–D) or double-stranded DNA (panels E–F) before visualization by
electron microscopy. All negatives were shot at 50000 magniﬁcation.
The bars represent 0.1mm.
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To ﬁnd out whether the stimulatory eﬀect of HMGB1 on
the catalytic activity of topo IIa could be due to a direct
physical interaction of HMGB1 with the enzyme, the pull-
down assay was used to investigate the possible existence
of the HMGB1–topo IIa interactions. To address this
question, recombinant GST alone or GST-HMGB1 were
immobilized on glutathione-agarose and incubated with
isolated human topo IIa. After extensive washing of the
beads, the bound proteins were resolved by SDS-PAGE
and subjected to western blotting and immunological
detection using an antibody speciﬁc to topo IIa. While
no topo IIa was found to be associated with GST alone,
a signiﬁcant fraction of topo IIa was bound to GST-
HMGB1 (Figure 5), suggesting that HMGB1 could
interact with topo IIa. Using a similar approach we
found that approximately similar amounts of topo IIa
were associated with HMGB1 or HMGB1-C, indicating
that the HMG-boxes, and not the polyanionic C-tail,
of HMGB1 were responsible for the interaction with
topo IIa (Figure 5). From Figure 5 (upper panel), it also
follows that both HMG-box domains, A and B, could
interact with topo IIa. Similar results were obtained when
DNAse I was included in the incubation buﬀer (Figure 5,
lower panel), demonstrating that the interaction of
HMGB1 with topo IIa was independent of DNA that
might have been associated with the isolated proteins.
Speciﬁcity of the ‘pull-down’ assay was veriﬁed with other
proteins known to interact with HMGB1 [p53, pRb,
(5,11,30)] as compared to those not binding to HMGB1
(E2F1, data not shown). Thus, the above ‘pull-down’
binding experiments strongly suggest that the interaction
of HMGB1 with topo IIa is speciﬁc.
HMGB1 stimulates bindingof topoisomerase IIatoDNA
HMGB1 has previously been reported to promote binding
of a plethora of transcription factors and other sequence-
speciﬁc proteins to their cognate sites (5). To ﬁnd out
whether the stimulatory eﬀect of HMGB1 on the catalytic
activity of topo IIa might have originated from enhanced
binding of the enzyme to DNA, the EMSA technique
(Electrophoretic Mobility Shift Assay) was used to study
the eﬀect of HMGB1 on topo IIa binding to DNA
containing a strong topo IIa recognition sequence. A
gradual increase in topo IIa binding to DNA was
observed when increasing amounts of HMGB1 were
added to a mixture of DNA and topo IIa (Figure 6,
arrow). Densitometric analysis revealed that the topo IIa
binding to DNA was up to  10-fold enhanced by
HMGB1. HMGB1 promoted topo IIa binding to DNA
(Step 1 in Figure 10) without formation of a ternary
complex topo IIa-HMGB1-DNA as no super-shift of the
topo IIa–DNA complex was detected by speciﬁc anti-
HMGB1 antibody (data not shown).
HMGB1 promotes DNA cleavage activity
by topoisomerase IIa
All catalytic activities of topo IIa are associated with the
ability of the enzyme to form transient double-stranded
breaks in the DNA duplex and to form covalent enzyme–
DNA intermediates, referred as to the ‘cleavable com-
plexes’. Topoisomerase IIa establishes two distinct
Figure 3. HMGB1 stimulates decatenation of kinetoplast DNA and relaxation of supercoiled DNA by topoisomerase IIa.( A) Decatenation of
kinetoplast DNA (kDNA) by topo IIa is stimulated by HMGB1. kDNA (0.2mg) was incubated with increasing concentrations of topo IIa (as
indicated) in the absence or presence of HMGB1 (1mM). (B) Domain structure of HMGB1, HMGB1-C, HMGB1 lacking the acidic C-tail
(depicted as oval); A, domain A; B, domain B. (C) HMGB1 stimulates decatenation of kDNA by topo IIa via the HMG-box domains. kDNA
(0.2mg) was incubated with topo IIa (2nM) in the presence or absence of increasing amounts of HMGB1, HMGB1-C, domain A or domain B (as
indicated). C, HMGB1-C. (D) HMGB1 stimulates relaxation of negatively supercoiled DNA by HMGB1. Relaxation of negatively supercoiled
pBR322 plasmid DNA ( 8nM) by diﬀerent concentrations of topo IIa (as indicated) in the presence or absence of recombinant HMGB1 (1mM),
378C for 45min. Decatenation and relaxation assays were carried out in the absence of PEG. Deproteinized DNA samples were resolved on 1%
agarose gels containing ethidium bromide (A and C) or without ethidium bromide (panel D). The gels are presented as negatives. FI, supercoiled
plasmid DNA; FII, relaxed closed-circular plasmid DNA. oc, nicked closed-circular DNA minicircle; rel, relaxed closed-circular DNA minicircle.
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DNA cleavage’ (corresponding to the ATP-free form of
the enzyme), and a ‘post-strand passage DNA cleavage’
(corresponding to the ATP-bound form) (31). To monitor
a ‘pre-strand passage DNA cleavage’, ATP is omitted
in the assays (Step 3 in Figure 10). A ‘post-strand
passage DNA cleavage’ is measured in the assays employ-
ing a non-hydrolyzable ATP analog, adenyl-50-yl
imidodiphosphate (AMP-PNP) (Step 4 in Figure 10).
When ATP is included in the cleavage assays, a mixture
of the two equilibria (Steps 3 and 4 in Figure 10)
is measured (31).
Figure 4. Stimulation of topo IIa activity by HMGB1 is not due to
the eﬀect of HMGB1 on DNA topology. (A) HMGB1 protein and
structure of HMGB1 domains A and B indicating positions of the
mutated intercalating amino acid residues (in red frames). (B) Purity of
HMGB1 and mutant as revealed by electrophoresis on an SDS–18%
polyacrylamide gel and Coomassie blue R-250 staining. Lane 1, wild-
type HMGB1; lane 2, HMGB1 mutant (F38A/F103A/I122A). A,
alanine; F, phenylalanine; I, isoleucine. (C) Alanine mutagenesis of
intercalating residues of HMGB1 abrogated the ability of HMGB1 to
introduce supercoils into DNA by topoisomerase I. Closed-circular
pBR322 plasmid DNA ( 9nM) was incubated with wheat germ
topoisomerase I in the absence or presence of HMGB1 or mutant (1, 2,
3 and 6mM, left to right). FI, supercoiled plasmid DNA; FII, relaxed
closed-circular plasmid DNA. (D) Both wild-type HMGB1 and
HMGB1 mutant can enhance decatenation of kDNA by human topo
IIa. Decatenation of kDNA was carried out as in Figure 3A. HMGB1
and mutant were at 1mM, topo IIa was 7.5 and 15nM. (E) HMGB1
does not stimulate decatenation of kDNA by E. coli topoisomerase IV.
Decatenation of kDNA by E. coli topoisomerase IV (0.15 and 0.6U)
was carried out as detailed in the Materials and Methods section using
HMGB1 or mutant (1 and 4mM, left to right). The DNA samples in
(C–E) were separated on 0.8% agarose gels without (C) or with (D–E)
ethidium bromide in the course of electrophoresis as detailed in the
Materials and Methods section. The gels are presented as negatives.
WT, wild-type HMGB1; Mut, triple-mutant (F38A/F103A/I122A) of
HMGB1.
Figure 6. HMGB1 stimulates binding of topoisomerase IIa to DNA.
32P-labeled 36-bp DNA duplex ( 75nM) containing a high-aﬃnity
binding site for topo IIa was mixed with topo IIa (75nM) and
increasing amounts of HMGB1 protein (0, 0.4, 0.6, 0.8 and 1.6mM,
lanes 2–6, respectively), followed by separation of unbound DNA
(free probe) and DNA–protein complexes on a 5% non-denaturing
polyacrylamide gel (EMSA) as detailed in Materials and Methods
section. The dried gel was subjected to PhosphorImaging. Lane 7,
HMGB1at 1.6mM. Arrowhead indicates mobility of the topo IIa–
DNA complex.
Figure 5. HMGB1 physically interacts with topoisomerase IIa.
HMGB1, HMGB1-C, domains A and B (expressed in E. coli and
fused proteins with GST at their N-termini) were bound to glutathione-
Sepharose beads (GST was used as a negative control). The beads were
then incubated with isolated human topo IIa, followed by extensive
washing of the beads, and boiling them in SDS-containing buﬀer. The
released proteins were resolved by electrophoresis on an SDS–7.5%
polyacrylamide gel, followed by western blotting and immunological
detection using polyclonal antibody speciﬁc to topo IIa. Input, 10% of
the total topo IIa used for the pull-down assay. Upper and lower PD
experiments were performed in the absence or presence of 10U of
DNAse I in the incubation buﬀer, respectively.
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catalytic activity of topo IIa by HMGB1 is due to
enhanced cleavage of the DNA substrate, the topo IIa-
mediated cleavage of the supercoiled plasmid DNA
was carried out. This assay allows one to quantify the
topo IIa-mediated double-stranded DNA cleavage by
detecting the conversion of covalently closed-circular
DNA to linear molecules. In the absence of drugs
stabilizing the ‘cleavable complexes’, the evaluation of
the DNA scission by topo IIa using ATP as a co-factor
was complicated by the appearance of individual
topoisomers in the course of relaxation of supercoiled
plasmid DNA (Figure 7A, +ATP). This was not the case
when DNA cleavage assay was performed either in the
absence of any cofactor (Figure 7A,  ATP) or using the
non-hydrolyzable ATP analog (Figure 7A, AMP-PNP).
The latter DNA cleavage experiments detected a signiﬁ-
cant ( 3-fold) HMGB1-mediated enhancement of DNA
scission by topo IIa, while no visible DNA scission was
observed when HMGB1 was incubated with supercoiled
DNA in the absence of topo IIa (Figure 7A).
The percentage of ‘cleavable complexes’ is usually very
low, but the levels of the cleavable complexes are
signiﬁcantly enhanced in the presence of topo II poisons
(such as etoposide) that aﬀect the DNA cleavage/
religation equilibrium (3). Similarly to the DNA cleavage
experiments in the absence of etoposide (Figure 7A),
HMGB1 could enhance >3-fold DNA cleavage by topo
IIa when etoposide was included in the reactions
(Figure 7B). Densitometric analysis of the percentage of
linearized DNA revealed that HMGB1 could stimulate
more eﬃciently (>3-fold) the ‘post-strand passage DNA
cleavage’ than the ‘pre-strand passage DNA cleavage’
( 2-fold), regardless of the presence or absence of
etoposide.
The eﬀect of HMGB1 on DNA cleavage by topo IIa
was also studied in reactions with increasing concentra-
tions of etoposide (0–100mM) and a ﬁxed amount of the
enzyme. Approximately  2–4 times higher percentage of
linear DNA was observed in the presence of HMGB1,
with the most prominent eﬀect at lower concentrations of
the drug (10–50mM), Figure 7C. The stimulatory eﬀect
of HMGB1 on formation of topo IIa–DNA cleavage
complexes was detectable over a range of enzyme:plasmid
ratios at ﬁxed concentrations of the drug and HMGB1
(data not shown).
HMGB1 doesnot promotethe ability oftopoisomerase IIa
toreligate cleaved DNA
The ability of topo IIa to cleave and religate double-
stranded DNA is essential for the regulation of DNA
Figure 7. HMGB1 stimulates DNA cleavage activity of topoisomerase IIa.( A) Eﬀect of HMGB1 on DNA cleavage activity of topo IIa in the
absence of etoposide. DNA cleavage reactions contained negatively supercoiled plasmid pBR322 ( 4nM), human topo IIa ( 8nM) and increasing
concentrations of HMGB1 (1, 2 and 3mM, left to right). ATP or a non-hydrolyzable ATP analog (AMP-PNP) were at 1mM. Arrowhead indicates
position of linearized DNA. (B) Eﬀect of HMGB1 on DNA cleavage activity of topo IIa in the presence of etoposide. The molar concentrations of
topo IIa and plasmid pBR322 were identical as in panel A. HMGB1 protein was at 1mM and etoposide at 50mM. (C) Eﬀect of HMGB1 on DNA
cleavage by topo IIa in the presence of increasing concentrations of etoposide. Negatively supercoiled plasmid DNA (4nM) was pre-incubated on ice
either with buﬀer (control) or HMGB1 (1mM) in the presence of 0–100mM etoposide. Cleavage reactions were initiated by addition of topo IIa
(8nM) and incubation was carried out at 378C for 15min. The cleavage complexes in A–C reactions were trapped by 1% SDS, followed by digestion
with proteinase K as detailed in Materials and Methods section. Deproteinized DNA samples were resolved on 1% agarose gels and subsequently
stained with ethidium bromide. FIII, HindIII-digested plasmid pBR322 (last right lanes in A and B) indicates mobility of linearized plasmid DNA.
FI, supercoiled plasmid DNA; FII, relaxed closed-circular plasmid DNA. The gels are presented as negatives. The percentage of cleaved plasmid
DNA was quantiﬁed from three independent cleavage experiments, each in duplicates, by ImageQuant TL (GE Healthcare). The average SD for the
data was <7%. DNA cleavage is expressed as percentage of initial uncleaved supercoiled plasmid pBR322. (open circle) In the absence (control) or in
the presence of HMGB1 (Filled circle).
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cleavage by topo IIa (Steps 3 and 4 in Figure 10), we have
asked whether HMGB1 could also inﬂuence the ability of
topo IIa to religate DNA using a heat-induced religation
assay (Step 5 in Figure 10). This assay is based on the
ﬁnding that religation activity of topo IIa is less sensitive
to variations in temperature than DNA cleavage activity
(32). By shifting the temperature from 37 to 658C before
termination with SDS, linearized DNA plasmid (gener-
ated by topo IIa-mediated DNA cleavage in the presence
of etoposide) is re-circularized in a time-dependent
manner. As shown in Figure 8, religation of DNA (as
revealed by the decrease of linearized DNA) was very
little, if any, enhanced by HMGB1, indicating that
HMGB1 could not promote religation of the cleaved
DNA by topoisomerase IIa. This was even more apparent
when religation assay was carried out at 758C (data not
shown), a temperature which has been recently shown
to inhibit more eﬃciently DNA cleavage by human topo
IIa without signiﬁcantly aﬀecting the ability of the enzyme
to religate DNA (33).
HMGB1 reduces inhibition ofcatalytic activity of
topoisomerase IIaby ICRF-193 andenhances
the rate ofATP hydrolysis
Topoisomerase IIa changes the topology of DNA by
coupling binding and hydrolysis of two ATP molecules to
the passage of one DNA duplex through a transient
double-stranded break in another DNA duplex. The
‘catalytic inhibitor’ ICRF-193 traps the topo IIa in the
closed-clamp intermediate form in the presence of ATP
(Step 6 in Figure 10), resulting in the inhibition of ATPase
activity, strand passage and catalytic turnover of the
enzyme (34). As shown in Figure 9A, HMGB1 could
partially relieve (<2-fold) the inhibitory eﬀect of ICRF-
193 on decatenation of kDNA by topo IIa. A slight, but
reproducible, decrease in the inhibitory eﬀect of ICRF-193
on topo IIa-mediated decatenation of kDNA was also
detected over a wide range of the drug concentrations
(data not shown). The latter results prompted us to
examine whether HMGB1 could modulate the rate of
ATP hydrolysis by topo IIa using thin layer chromato-
graphy enabling to separate released phosphate from
ATP upon incubation of [g-
32P]ATP with topo IIa and
negatively supercoiled plasmid DNA (24). Quantiﬁcation
of the released phosphate revealed that HMGB1 could
enhance (<2-fold) the rate of ATP hydrolysis by topo IIa
(Figure 9B). As the stimulatory eﬀect of HMGB1 on
ATPase activity of topo IIa is relatively modest, the DNA
binding and cleavage are most likely the major control
steps by which HMGB1 modulates the catalytic activity
of the enzyme.
Figure 8. HMGB1 does not signiﬁcantly aﬀect DNA religation by
topoisomerase IIa. DNA cleavage reactions contained negatively
supercoiled plasmid DNA (4nM),5 0 mM etoposide in the absence
(control) or presence of HMGB1 (1mM). Cleavage reactions were
initiated by addition of topo IIa (8nM) and incubation at 378C for
15min. The incubation temperature was then shifted to 658Ct o
suppress cleavage and to promote religation as described in Materials
and Methods section. A representative ethidium bromide-stained
agarose gel of the DNA religation assay is shown (religation times
were 0, 2.5, 5, 10, 20, 30 and 40min, left to right). The percentage of
linear DNA was estimated by the Multi Gauge software using imaging
system LAS-3000 (Fuji). Each curve represents the average of 2–3
independent assays. The average SD for the data was <8%. The
amount of linearized plasmid molecules in the cleavage reaction
containing or lacking HMGB1 was expressed as 100%. (open circle)
in the absence (control) or in the presence of HMGB1 (ﬁlled circle). FI,
supercoiled plasmid DNA; FII, relaxed closed-circular plasmid DNA;
FIII, linear plasmid DNA.
Figure 9. HMGB1 enhances ATP hydrolysis by topoisomerase IIa.
(A) HMGB1 reduces inhibition of catalytic activity of topo IIa by
ICRF-193. kDNA (0.2mg) was decatenated with topo IIa (2nM) in the
absence or presence of 10mM ICRF-193. Some decatenation reactions
contained HMGB1 (0.5, 1.5 and 3mM, left to right). Decatenation was
carried out as detailed in the Materials and Methods section. Due to
the absence of ethidium bromide in the agarose gel in the course of
electrophoresis, the decatenated minicircles migrated as single bands
comprising both nicked and closed-circular DNA (designated as oc and
rel in Figures 3 and 4). A representative ethidium bromide-stained 1%
agarose gel (presented as a negative) is shown. (B) HMGB1 enhances
the rate of ATP hydrolysis by topo IIa. ATP hydrolysis by topo IIa
(5nM) was studied in reactions containing 1mM cold ATP and
[g-
32P]ATP and negatively supercoiled plasmid pBR322 (50nM). The
ATP hydrolysis (as determined by a time-dependent release of free PO4)
was measured by thin layer chromatography (24) and quantiﬁed by
PhosporImaging. Data represent the average of two independent
experiments.
5010 Nucleic Acids Research, 2007, Vol. 35, No. 15DISCUSSION
A distinctive property of living systems is that biochemical
processes proceed in a medium which is highly crowded
with macromolecules (35). It has previously been shown
that molecular crowding has a strong eﬀect both on
equilibrium and on the rate of reactions involving
macromolecules (35). Polyethylene glycol (PEG) as a
volume excluding agent may imitate the conditions under
which HMGB1 is able to facilitate (non-covalent) inter-
molecular associations of DNA helices with subsequent
ligation by limiting amounts of enzymes (21,27,36,37
and this study). The observed interlinking of circular,
covalently closed DNA molecules by topo IIa in the
presence of HMGB1 is likely a consequence of the
PEG-mediated increase of local DNA and protein
concentrations. Apart from increase of the DNA con-
centration, the presence of PEG obviously increases the
concentration of HMGB1 in the catenation reaction
(typically  1mM in the test tube) which may then
approach the expected actual concentration of HMGB1
in the cell nucleus,  25mM (assuming  10
6 copies of
HMGB1 per cell, the volume of the cell nucleus
6.5 10
 11ml, and disregarding the contribution of
nuclear crowding agents which would otherwise
likely lead to even higher concentration of HMGB1
in the nucleus). As higher amounts of topo IIa can
promote DNA catenation in the absence of other factors
(38), there has been a possibility that the observed DNA
catenation in the presence of HMGB1 might have had
arisen solely as a consequence of a PEG-induced increase
in the topo IIa concentration. However, this seems
unlikely as PEG itself does not promote DNA catenation
by low amounts of topo IIa when HMGB1 is absent. A
variety of polycations, including spermidine and histone
H1, promote catenation, and this is most likely due to
compaction of the DNA substrate into aggregates with
high local DNA concentration favoring the catenated
state (39). HMGB1 can promote interlocking of DNA
rings by topo IIa only if a crowding agent is present in the
course of the catenation reaction. This may reﬂect the fact
that unlike DNA binding of the polyvalent cations,
histone H1 or other nuclear proteins (such as nucleolin,
DNA-PKcs and Ku70/80) (39,40 and references therein),
aggregation of HMGB1–DNA complexes is much less
apparent in diluted solutions (14,41,42).
HMGB1 promotes not only topo IIa-mediated catena-
tion of circular DNA, but it can also enhance decatenation
of kDNA and relaxation of negatively supercoiled
DNA in vitro. The catalytic cycle of topo IIa depends
on a coordinate function of several catalytic steps of the
enzyme (Figure 10). The ﬁrst step includes binding of the
enzyme to DNA (Step 1 in Figure 10) which has been
demonstrated to be signiﬁcantly enhanced by HMGB1.
HMGB1 stimulates catalytic activity of topo IIa by
promoting DNA cleavage (Steps 3–4 in Figure 10),
without aﬀecting the pattern of speciﬁc cleavage sites on
DNA (data not shown). Although both ‘pre-strand’ and
‘post-strand passage DNA cleavage’ steps (Steps 3 and 4,
respectively in Figure 10) are stimulated by HMGB1,
the stimulatory eﬀect by HMGB1 is more prominent
at the ‘post-strand passage DNA cleavage’ step of the
catalytic cycle of the enzyme. A possible explanation of
the HMGB1-mediated stimulation of DNA cleavage by
topo IIa is enhanced binding of the enzyme to DNA.
The latter may be a consequence of the reported ability
of HMGB1 to act as a ‘DNA chaperone’ [e.g. by bending
DNA, (6–8)] and/or due to direct interaction of the
protein with topo IIa.
Topo IIa (3,23,43), like HMGB1 (7,8,14,44,45), can
bind preferentially to supercoiled plasmid (including non
B-DNA structures such as Z-DNA and four-way junc-
tions) as compared to the linear B-DNA. Whether the
reported preferential binding of HMGB1 to distorted or
non B-type DNA structures contributes to recognition of
topo IIa-speciﬁc DNA-binding sites/structures remains to
be established. HMGB1 has also been previously reported
to change DNA topology by unwinding the double-helical
DNA or introducing negative supercoils in DNA
(13,14,20,28). However, the HMGB1-mediated enhance-
ment of decatenation by human topo IIa is similar when
assayed using an HMGB1 mutant that does not aﬀect
DNA topology. In addition, the activity of E. coli
topoisomerase IV, a prokaryotic type-II topoisomerase
that has evolved independently from HMG-box proteins,
is not inﬂuenced by changes in DNA topology induced by
Figure 10. HMGB1 and catalytic cycle of DNA topoisomerase IIa. The
drawing is adapted from ref. (46). The ATPase domains of topo IIa
(light green) and the core domains (dark green) are depicted (the
C-terminal domain which is not required for the enzymatic activity of
topo IIa, is not shown). Binding of two double-stranded DNA duplexes
G (in red) and T (in blue) initiates the catalytic cycle (Step 1). Upon
binding of two ATP molecules (red ﬁlled circles), the two ATPase
domains dimerize (Step 2). Cleavage of G duplex in Step 3 (‘pre-strand
passage DNA cleavage’) is followed by passage of the T duplex through
the double-stranded break in the G duplex (‘Gpost-strand passage
DNA cleavage’) (Step 4). Religation of the G duplex and hydrolysis of
ATP proceeds in Step 5. Two molecules of ADP dissociate in Step 6,
followed by release of the T duplex through the C-terminal part of topo
IIa. Reopening of the ATPase domains allows dissociation of the G
duplex (Step 7) to regenerate the enzyme for the next catalytic cycle.
Individual steps of the topo II catalytic cycle which are stimulated the
most by HMGB1 are indicated by arrows: Step 1 (DNA binding,
Figure 6), Steps 3 and 4 (DNA cleavage, Figure 7). The dashed arrow
indicates the HMGB1-mediated partial relief of topo IIa inhibition by
ICRF-193 in Step 6 (Figure 9).
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stimulatory eﬀect of HMGB1 on the catalytic activity of
the enzyme depends not only on DNA–protein interac-
tions but also on protein–protein interactions. The fact
that EMSA assay did not detect any ternary DNA–topo
IIa–HMGB1 complex does not necessarily mean the lack
of existence of such a complex. It is possible that HMGB1
can ‘deliver’ the topo IIa to its binding/cleavage sites by
forming a ternary complex which is transient and
unstable. This idea is in agreement with previous reports
demonstrating the ability of HMGB1 to enhance the
binding a plethora of sequence-speciﬁc proteins to their
cognate DNA sites without formation of ternary com-
plexes, despite the detection of the corresponding protein–
protein interactions in pull-down assays (5,8).
ICRF-193 inhibits Step 6 of the catalytic cycle of topo
IIa (Figure 10), the ATP hydrolysis, by trapping the
enzyme on the DNA in the closed-clamp form (34).
HMGB1 can partially relieve the inhibitory eﬀect of
ICRF-193 on decatenation of kDNA by topo IIa.
HMGB1 could not signiﬁcantly stimulate resealing of
double-stranded breaks by topo IIa (religation Step 5
in Figure 10) using the temperature-induced religation
assay. As the stimulatory eﬀect of HMGB1 on the ATP
hydrolysis by topo IIa (and even less on religation of
double-stranded breaks) is relatively modest, the enhanced
DNA binding of topo IIa and consequently higher DNA
cleavage represent the major control steps by which
HMGB1 modulates the catalytic activity of the enzyme.
An important question remains whether HMGB1
enhances the activity of topo IIa in vivo, and whether
the possible activation involves direct stimulation of the
enzymatic activity (as a result of mutual interactions) and/
or de novo synthesis of the enzyme. The latter possibility
may be indicated by our luciferase reporter gene assays
demonstrating a signiﬁcant (>10-fold) transactivation of
the human topo II  promoter by HMGB1 in Saos-2 cells
(S ˇ tros et al., unpublished data).
Topo IIa expression is associated with a higher cell
proliferation rate, and the level of topo IIa is very low in
G1 phase, it increases in S phase, and is maximal in G2/M
(1,3,47). Although HMGB1 is expressed throughout the
cell cycle with no signiﬁcant variations (5), the protein is
clearly over-expressed in most human tumors, including
breast carcinoma, melanoma, gastrointestinal stromal
tumors, colon carcinomas and acute myeloblastic leuke-
mia (48 and references therein). Further experiments are
needed to clarify whether this over-expression aﬀects the
cellular activity and expression of topo IIa, and if so,
whether it contributes to the reported enhanced topo IIa
activity in tumors (49,50).
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